ID   5NT3A_HUMAN             Reviewed;         336 AA.
AC   Q9H0P0; A8K253; B2RAA5; B8ZZC4; Q6IPZ1; Q6NXS6; Q7L3G6; Q9P0P5;
AC   Q9UC42; Q9UC43; Q9UC44; Q9UC45;
DT   13-SEP-2005, integrated into UniProtKB/Swiss-Prot.
DT   14-NOV-2006, sequence version 3.
DT   10-MAY-2017, entry version 153.
DE   RecName: Full=Cytosolic 5'-nucleotidase 3A {ECO:0000305|PubMed:15968458, ECO:0000305|PubMed:24603684};
DE            EC=3.1.3.5 {ECO:0000269|PubMed:15968458, ECO:0000269|PubMed:24603684};
DE   AltName: Full=7-methylguanosine phosphate-specific 5'-nucleotidase {ECO:0000305|PubMed:24603684};
DE            Short=7-methylguanosine nucleotidase;
DE            EC=3.1.3.91 {ECO:0000269|PubMed:24603684};
DE   AltName: Full=Cytosolic 5'-nucleotidase 3;
DE   AltName: Full=Cytosolic 5'-nucleotidase III;
DE            Short=cN-III;
DE   AltName: Full=Pyrimidine 5'-nucleotidase 1;
DE            Short=P5'N-1;
DE            Short=P5N-1;
DE            Short=PN-I;
DE   AltName: Full=Uridine 5'-monophosphate hydrolase 1;
DE   AltName: Full=p36;
GN   Name=NT5C3A; Synonyms=NT5C3, P5N1, UMPH1; ORFNames=HSPC233;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND PROTEIN SEQUENCE OF
RP   92-111; 131-155; 226-240; 268-296 AND 313-332.
RC   TISSUE=Placenta;
RX   PubMed=10942414;
RA   Amici A., Emanuelli M., Raffaelli N., Ruggieri S., Saccucci F.,
RA   Magni G.;
RT   "Human erythrocyte pyrimidine 5'-nucleotidase, PN-I, is identical to
RT   p36, a protein associated to lupus inclusion formation in response to
RT   alpha-interferon.";
RL   Blood 96:1596-1598(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 3), TISSUE SPECIFICITY, AND
RP   VARIANT P5ND VAL-137.
RX   PubMed=11369620; DOI=10.1182/blood.V97.11.3327;
RA   Marinaki A.M., Escuredo E., Duley J.A., Simmonds H.A., Amici A.,
RA   Naponelli V., Magni G., Seip M., Ben-Bassat I., Harley E.H.,
RA   Thein S.L., Rees D.C.;
RT   "Genetic basis of hemolytic anemia caused by pyrimidine 5'
RT   nucleotidase deficiency.";
RL   Blood 97:3327-3332(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Kidney;
RX   PubMed=11230166; DOI=10.1101/gr.GR1547R;
RA   Wiemann S., Weil B., Wellenreuther R., Gassenhuber J., Glassl S.,
RA   Ansorge W., Boecher M., Bloecker H., Bauersachs S., Blum H.,
RA   Lauber J., Duesterhoeft A., Beyer A., Koehrer K., Strack N.,
RA   Mewes H.-W., Ottenwaelder B., Obermaier B., Tampe J., Heubner D.,
RA   Wambutt R., Korn B., Klein M., Poustka A.;
RT   "Towards a catalog of human genes and proteins: sequencing and
RT   analysis of 500 novel complete protein coding human cDNAs.";
RL   Genome Res. 11:422-435(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3).
RC   TISSUE=Brain cortex, and Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R.,
RA   Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H.,
RA   Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A.,
RA   Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J.,
RA   Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A.,
RA   Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S.,
RA   Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M.,
RA   Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C.,
RA   Latreille P., Miller N., Johnson D., Murray J., Woessner J.P.,
RA   Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J.,
RA   Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L.,
RA   Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R.,
RA   Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K.,
RA   Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S.,
RA   Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M.,
RA   Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R.,
RA   Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D.,
RA   Waterston R.H., Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Brain, Lung, Muscle, and Prostate;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 29-336 (ISOFORM 2).
RC   TISSUE=Umbilical cord blood;
RX   PubMed=11042152; DOI=10.1101/gr.140200;
RA   Zhang Q.-H., Ye M., Wu X.-Y., Ren S.-X., Zhao M., Zhao C.-J., Fu G.,
RA   Shen Y., Fan H.-Y., Lu G., Zhong M., Xu X.-R., Han Z.-G., Zhang J.-W.,
RA   Tao J., Huang Q.-H., Zhou J., Hu G.-X., Gu J., Chen S.-J., Chen Z.;
RT   "Cloning and functional analysis of cDNAs with open reading frames for
RT   300 previously undefined genes expressed in CD34+ hematopoietic
RT   stem/progenitor cells.";
RL   Genome Res. 10:1546-1560(2000).
RN   [10]
RP   PROTEIN SEQUENCE OF 83-95; 131-147; 226-240; 268-296 AND 311-329,
RP   INDUCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=8557639; DOI=10.1074/jbc.271.20.11595;
RA   Rich S.A., Bose M., Tempst P., Rudofsky U.H.;
RT   "Purification, microsequencing, and immunolocalization of p36, a new
RT   interferon-alpha-induced protein that is associated with human lupus
RT   inclusions.";
RL   J. Biol. Chem. 271:1118-1126(1996).
RN   [11]
RP   CHARACTERIZATION OF P5ND VAL-137; PRO-181; SER-229 AND ARG-280.
RX   PubMed=15604219; DOI=10.1182/blood-2004-10-3895;
RA   Chiarelli L.R., Bianchi P., Fermo E., Galizzi A., Iadarola P.,
RA   Mattevi A., Zanella A., Valentini G.;
RT   "Functional analysis of pyrimidine 5'-nucleotidase mutants causing
RT   nonspherocytic hemolytic anemia.";
RL   Blood 105:3340-3345(2005).
RN   [12]
RP   FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, CATALYTIC ACTIVITY,
RP   CHARACTERIZATION OF VARIANTS P5ND SER-229 AND ARG-280, AND MUTAGENESIS
RP   OF ASP-88; PHE-89; ASP-90; GLU-135; ASP-232; PHE-233 AND ASP-234.
RX   PubMed=15968458; DOI=10.1007/s00018-005-5135-y;
RA   Amici A., Ciccioli K., Naponelli V., Raffaelli N., Magni G.;
RT   "Evidence for essential catalytic determinants for human erythrocyte
RT   pyrimidine 5'-nucleotidase.";
RL   Cell. Mol. Life Sci. 62:1613-1620(2005).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [15]
RP   FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=24603684; DOI=10.1371/journal.pone.0090915;
RA   Monecke T., Buschmann J., Neumann P., Wahle E., Ficner R.;
RT   "Crystal structures of the novel cytosolic 5'-nucleotidase IIIB
RT   explain its preference for m7GMP.";
RL   PLoS ONE 9:90915-90915(2014).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.67 ANGSTROMS) OF 64-336 IN COMPLEX WITH
RP   PHOSPHATE AND MAGNESIUM IONS, ACTIVE SITE, AND METAL BINDING.
RX   PubMed=17405878; DOI=10.1074/jbc.M700917200;
RA   Wallden K., Stenmark P., Nyman T., Flodin S., Graeslund S.,
RA   Loppnau P., Bianchi V., Nordlund P.;
RT   "Crystal structure of human cytosolic 5'-nucleotidase II: insights
RT   into allosteric regulation and substrate recognition.";
RL   J. Biol. Chem. 282:17828-17836(2007).
RN   [17]
RP   VARIANT P5ND SER-229.
RX   PubMed=12930399; DOI=10.1046/j.1365-2141.2003.04532.x;
RA   Bianchi P., Fermo E., Alfinito F., Vercellati C., Baserga M.,
RA   Ferraro F., Guzzo I., Rotoli B., Zanella A.;
RT   "Molecular characterization of six unrelated Italian patients affected
RT   by pyrimidine 5'-nucleotidase deficiency.";
RL   Br. J. Haematol. 122:847-851(2003).
RN   [18]
RP   VARIANTS P5ND PRO-181 AND ARG-280, IDENTIFICATION OF ISOFORM 4, TISSUE
RP   SPECIFICITY, AND CHARACTERIZATION OF VARIANTS P5ND PRO-181 AND
RP   ARG-280.
RX   PubMed=15238149; DOI=10.1111/j.1365-2141.2004.05029.x;
RA   Kanno H., Takizawa T., Miwa S., Fujii H.;
RT   "Molecular basis of Japanese variants of pyrimidine 5'-nucleotidase
RT   deficiency.";
RL   Br. J. Haematol. 126:265-271(2004).
RN   [19]
RP   VARIANTS P5ND PRO-181; ARG-207 AND THR-297.
RX   PubMed=16461318;
RA   Manco L., Relvas L., Silva Pinto C., Pereira J., Almeida A.B.,
RA   Ribeiro M.L.;
RT   "Molecular characterization of five Portuguese patients with
RT   pyrimidine 5'-nucleotidase deficient hemolytic anemia showing three
RT   new P5'N-I mutations.";
RL   Haematologica 91:266-267(2006).
RN   [20]
RP   CHARACTERIZATION OF VARIANTS P5ND ARG-113; ARG-207 AND THR-297.
RX   PubMed=18499901; DOI=10.1016/j.bcmd.2007.10.005;
RA   Chiarelli L.R., Morera S.M., Galizzi A., Fermo E., Zanella A.,
RA   Valentini G.;
RT   "Molecular basis of pyrimidine 5'-nucleotidase deficiency caused by 3
RT   newly identified missense mutations (c.187T>C, c.469G>C and c.740T>C)
RT   and a tabulation of known mutations.";
RL   Blood Cells Mol. Dis. 40:295-301(2008).
RN   [21]
RP   VARIANT P5ND GLY-95.
RX   PubMed=25153905; DOI=10.1016/j.bcmd.2014.05.009;
RA   Dos Santos A., Dantas L.E., Traina F., Albuquerque D.M., Chaim E.A.,
RA   Saad S.T.;
RT   "Pyrimidine-5'-nucleotidase Campinas, a new mutation (p.R56G) in the
RT   NT5C3 gene associated with pyrimidine-5'-nucleotidase type I
RT   deficiency and influence of Gilbert's Syndrome on clinical
RT   expression.";
RL   Blood Cells Mol. Dis. 53:246-252(2014).
CC   -!- FUNCTION: Nucleotidase which shows specific activity towards
CC       cytidine monophosphate (CMP) and 7-methylguanosine monophosphate
CC       (m(7)GMP) (PubMed:24603684). CMP seems to be the preferred
CC       substrate (PubMed:15968458). {ECO:0000269|PubMed:15968458,
CC       ECO:0000269|PubMed:24603684}.
CC   -!- CATALYTIC ACTIVITY: N(7)-methyl-GMP + H(2)O = N(7)-methyl-
CC       guanosine + phosphate. {ECO:0000269|PubMed:24603684}.
CC   -!- CATALYTIC ACTIVITY: CMP + H(2)O = cytidine + phosphate.
CC       {ECO:0000269|PubMed:15968458}.
CC   -!- CATALYTIC ACTIVITY: A 5'-ribonucleotide + H(2)O = a ribonucleoside
CC       + phosphate. {ECO:0000269|PubMed:15968458}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=15 uM for m(7)GMP (at 37 degrees Celsius)
CC         {ECO:0000269|PubMed:24603684};
CC         KM=66 uM for CMP {ECO:0000269|PubMed:15968458};
CC         KM=80 uM for CMP (at 37 degrees Celsius)
CC         {ECO:0000269|PubMed:24603684};
CC   -!- SUBUNIT: Monomer. {ECO:0000269|PubMed:17405878}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Endoplasmic reticulum.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=2;
CC         IsoId=Q9H0P0-4; Sequence=Displayed;
CC       Name=1; Synonyms=P5N-I;
CC         IsoId=Q9H0P0-1; Sequence=VSP_021565;
CC       Name=3; Synonyms=p36;
CC         IsoId=Q9H0P0-2; Sequence=VSP_015623;
CC       Name=4; Synonyms=P5N-R;
CC         IsoId=Q9H0P0-3; Sequence=VSP_015624;
CC   -!- TISSUE SPECIFICITY: Isoforms 1, 3 and 4 are expressed in
CC       reticulocytes. Isoform 4 is hardly detectable in bone marrow and
CC       fetal liver. {ECO:0000269|PubMed:11369620,
CC       ECO:0000269|PubMed:15238149}.
CC   -!- INDUCTION: Isoform 2 is induced by interferon alpha in Raji cells
CC       in association with lupus inclusions.
CC       {ECO:0000269|PubMed:8557639}.
CC   -!- DISEASE: P5N deficiency (P5ND) [MIM:266120]: Autosomal recessive
CC       condition causing hemolytic anemia characterized by marked
CC       basophilic stippling and the accumulation of high concentrations
CC       of pyrimidine nucleotides within the erythrocyte. It is implicated
CC       in the anemia of lead poisoning and is possibly associated with
CC       learning difficulties. {ECO:0000269|PubMed:11369620,
CC       ECO:0000269|PubMed:12930399, ECO:0000269|PubMed:15238149,
CC       ECO:0000269|PubMed:15604219, ECO:0000269|PubMed:15968458,
CC       ECO:0000269|PubMed:16461318, ECO:0000269|PubMed:18499901,
CC       ECO:0000269|PubMed:25153905}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the pyrimidine 5'-nucleotidase family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAF36153.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=AAG33630.1; Type=Frameshift; Positions=Several; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF312735; AAG33630.1; ALT_SEQ; mRNA.
DR   EMBL; AL136716; CAB66650.1; -; mRNA.
DR   EMBL; AK290118; BAF82807.1; -; mRNA.
DR   EMBL; AK314109; BAG36802.1; -; mRNA.
DR   EMBL; CR533518; CAG38549.1; -; mRNA.
DR   EMBL; AC074338; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC083863; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471073; EAW94007.1; -; Genomic_DNA.
DR   EMBL; CH471073; EAW94008.1; -; Genomic_DNA.
DR   EMBL; BC013292; AAH13292.2; -; mRNA.
DR   EMBL; BC015856; AAH15856.2; -; mRNA.
DR   EMBL; BC066914; AAH66914.1; -; mRNA.
DR   EMBL; BC071652; AAH71652.2; -; mRNA.
DR   EMBL; AF151067; AAF36153.1; ALT_INIT; mRNA.
DR   CCDS; CCDS34616.1; -. [Q9H0P0-4]
DR   CCDS; CCDS34617.1; -. [Q9H0P0-1]
DR   CCDS; CCDS55101.1; -. [Q9H0P0-3]
DR   RefSeq; NP_001002009.1; NM_001002009.2. [Q9H0P0-1]
DR   RefSeq; NP_001002010.1; NM_001002010.2. [Q9H0P0-4]
DR   RefSeq; NP_001159590.1; NM_001166118.2. [Q9H0P0-3]
DR   RefSeq; NP_057573.2; NM_016489.12. [Q9H0P0-1]
DR   RefSeq; XP_011513711.1; XM_011515409.2. [Q9H0P0-3]
DR   UniGene; Hs.487933; -.
DR   PDB; 2CN1; X-ray; 2.67 A; A=64-336.
DR   PDB; 2JGA; X-ray; 3.01 A; A=64-336.
DR   PDB; 2VKQ; X-ray; 2.50 A; A=64-336.
DR   PDBsum; 2CN1; -.
DR   PDBsum; 2JGA; -.
DR   PDBsum; 2VKQ; -.
DR   ProteinModelPortal; Q9H0P0; -.
DR   SMR; Q9H0P0; -.
DR   BioGrid; 119408; 21.
DR   IntAct; Q9H0P0; 11.
DR   MINT; MINT-3065844; -.
DR   STRING; 9606.ENSP00000242210; -.
DR   DEPOD; Q9H0P0; -.
DR   iPTMnet; Q9H0P0; -.
DR   PhosphoSitePlus; Q9H0P0; -.
DR   BioMuta; NT5C3A; -.
DR   DMDM; 117949804; -.
DR   EPD; Q9H0P0; -.
DR   PaxDb; Q9H0P0; -.
DR   PeptideAtlas; Q9H0P0; -.
DR   PRIDE; Q9H0P0; -.
DR   DNASU; 51251; -.
DR   Ensembl; ENST00000242210; ENSP00000242210; ENSG00000122643. [Q9H0P0-4]
DR   Ensembl; ENST00000381626; ENSP00000371039; ENSG00000122643. [Q9H0P0-3]
DR   Ensembl; ENST00000396152; ENSP00000379456; ENSG00000122643. [Q9H0P0-1]
DR   Ensembl; ENST00000405342; ENSP00000385261; ENSG00000122643. [Q9H0P0-1]
DR   Ensembl; ENST00000409467; ENSP00000387166; ENSG00000122643. [Q9H0P0-3]
DR   Ensembl; ENST00000620705; ENSP00000484415; ENSG00000122643. [Q9H0P0-4]
DR   GeneID; 51251; -.
DR   KEGG; hsa:51251; -.
DR   UCSC; uc003tdi.5; human. [Q9H0P0-4]
DR   CTD; 51251; -.
DR   DisGeNET; 51251; -.
DR   GeneCards; NT5C3A; -.
DR   HGNC; HGNC:17820; NT5C3A.
DR   HPA; HPA010630; -.
DR   HPA; HPA029058; -.
DR   MalaCards; NT5C3A; -.
DR   MIM; 266120; phenotype.
DR   MIM; 606224; gene.
DR   neXtProt; NX_Q9H0P0; -.
DR   OpenTargets; ENSG00000122643; -.
DR   Orphanet; 35120; Hemolytic anemia due to pyrimidine 5' nucleotidase deficiency.
DR   PharmGKB; PA31802; -.
DR   eggNOG; KOG3128; Eukaryota.
DR   eggNOG; ENOG410ZQJ8; LUCA.
DR   GeneTree; ENSGT00390000012959; -.
DR   HOVERGEN; HBG059750; -.
DR   KO; K01081; -.
DR   OMA; AGVYHSN; -.
DR   OrthoDB; EOG091G0BCN; -.
DR   PhylomeDB; Q9H0P0; -.
DR   TreeFam; TF314663; -.
DR   BRENDA; 3.1.3.91; 2681.
DR   Reactome; R-HSA-73621; Pyrimidine catabolism.
DR   SABIO-RK; Q9H0P0; -.
DR   EvolutionaryTrace; Q9H0P0; -.
DR   GeneWiki; NT5C3; -.
DR   GenomeRNAi; 51251; -.
DR   PRO; PR:Q9H0P0; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   Bgee; ENSG00000122643; -.
DR   ExpressionAtlas; Q9H0P0; baseline and differential.
DR   Genevisible; Q9H0P0; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0008665; F:2'-phosphotransferase activity; TAS:UniProtKB.
DR   GO; GO:0008253; F:5'-nucleotidase activity; IDA:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; NAS:UniProtKB.
DR   GO; GO:0000166; F:nucleotide binding; IEA:UniProtKB-KW.
DR   GO; GO:0046085; P:adenosine metabolic process; IEA:Ensembl.
DR   GO; GO:0009117; P:nucleotide metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0046135; P:pyrimidine nucleoside catabolic process; TAS:Reactome.
DR   GO; GO:0006213; P:pyrimidine nucleoside metabolic process; NAS:UniProtKB.
DR   Gene3D; 3.40.50.1000; -; 1.
DR   InterPro; IPR023214; HAD-like_dom.
DR   InterPro; IPR006434; Pyrimidine_nucleotidase_eu.
DR   Pfam; PF05822; UMPH-1; 1.
DR   SFLD; SFLDG01128; C1.4:_5'-Nucleotidase_Like; 1.
DR   SUPFAM; SSF56784; SSF56784; 1.
DR   TIGRFAMs; TIGR01544; HAD-SF-IE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Disease mutation; Endoplasmic reticulum;
KW   Hydrolase; Magnesium; Metal-binding; Nucleotide metabolism;
KW   Nucleotide-binding; Phosphoprotein; Reference proteome; Transferase.
FT   CHAIN         1    336       Cytosolic 5'-nucleotidase 3A.
FT                                /FTId=PRO_0000064387.
FT   REGION      203    204       Substrate binding.
FT                                {ECO:0000269|PubMed:17405878}.
FT   ACT_SITE     88     88       Nucleophile.
FT                                {ECO:0000269|PubMed:17405878}.
FT   ACT_SITE     90     90       Proton donor.
FT                                {ECO:0000269|PubMed:17405878}.
FT   METAL        88     88       Magnesium. {ECO:0000269|PubMed:17405878}.
FT   METAL        90     90       Magnesium; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:17405878}.
FT   METAL       277    277       Magnesium. {ECO:0000269|PubMed:17405878}.
FT   BINDING     135    135       CMP. {ECO:0000250|UniProtKB:Q9W197}.
FT   BINDING     135    135       N(7)-methyl-GMP.
FT                                {ECO:0000250|UniProtKB:Q9W197}.
FT   BINDING     156    156       N(7)-methyl-GMP.
FT                                {ECO:0000250|UniProtKB:Q9W197}.
FT   BINDING     252    252       Substrate.
FT                                {ECO:0000250|UniProtKB:Q9D020}.
FT   MOD_RES     278    278       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9D020}.
FT   VAR_SEQ       1     51       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:15238149}.
FT                                /FTId=VSP_015624.
FT   VAR_SEQ       1     50       MRAPSMDRAAVARVGAVASASVCALVAGVVLAQYIFTLKRK
FT                                TGRKTKIIE -> MTNQESAVHVK (in isoform 1).
FT                                {ECO:0000303|PubMed:11369620,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_021565.
FT   VAR_SEQ       1     50       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:11369620,
FT                                ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_015623.
FT   VARIANT      95     95       R -> G (in P5ND).
FT                                {ECO:0000269|PubMed:25153905}.
FT                                /FTId=VAR_073160.
FT   VARIANT     113    113       C -> R (in P5ND; reduced catalytic
FT                                activity especially towards UMP).
FT                                {ECO:0000269|PubMed:18499901}.
FT                                /FTId=VAR_073161.
FT   VARIANT     137    137       D -> V (in P5ND; reduced catalytic
FT                                activity; dbSNP:rs104894025).
FT                                {ECO:0000269|PubMed:11369620,
FT                                ECO:0000269|PubMed:15604219}.
FT                                /FTId=VAR_023511.
FT   VARIANT     181    181       L -> P (in P5ND; reduced catalytic
FT                                activity in vitro; reduced protein
FT                                stability in vivo, probably through
FT                                increased proteasomal degradation).
FT                                {ECO:0000269|PubMed:15238149,
FT                                ECO:0000269|PubMed:15604219,
FT                                ECO:0000269|PubMed:16461318}.
FT                                /FTId=VAR_023512.
FT   VARIANT     207    207       G -> R (in P5ND; reduced catalytic
FT                                activity especially towards UMP).
FT                                {ECO:0000269|PubMed:16461318,
FT                                ECO:0000269|PubMed:18499901}.
FT                                /FTId=VAR_073162.
FT   VARIANT     229    229       N -> S (in P5ND; almost complete loss of
FT                                catalytic activity; dbSNP:rs104894028).
FT                                {ECO:0000269|PubMed:12930399,
FT                                ECO:0000269|PubMed:15604219,
FT                                ECO:0000269|PubMed:15968458}.
FT                                /FTId=VAR_023513.
FT   VARIANT     280    280       G -> R (in P5ND; greatly reduced
FT                                catalytic activity; dbSNP:rs104894029).
FT                                {ECO:0000269|PubMed:15238149,
FT                                ECO:0000269|PubMed:15604219,
FT                                ECO:0000269|PubMed:15968458}.
FT                                /FTId=VAR_023514.
FT   VARIANT     297    297       I -> T (in P5ND).
FT                                {ECO:0000269|PubMed:16461318,
FT                                ECO:0000269|PubMed:18499901}.
FT                                /FTId=VAR_073163.
FT   MUTAGEN      88     88       D->N: Loss of nucleotidase and
FT                                phosphotransferase activity.
FT                                {ECO:0000269|PubMed:15968458}.
FT   MUTAGEN      89     89       F->A: Almost complete loss of
FT                                nucleotidase and phosphotransferase
FT                                activity. {ECO:0000269|PubMed:15968458}.
FT   MUTAGEN      90     90       D->N: Loss of nucleotidase and
FT                                phosphotransferase activity.
FT                                {ECO:0000269|PubMed:15968458}.
FT   MUTAGEN     135    135       E->D: No effect on nucleotidase activity.
FT                                Almost complete loss of
FT                                phosphotransferase activity.
FT                                {ECO:0000269|PubMed:15968458}.
FT   MUTAGEN     232    232       D->N: No effect on nucleotidase and
FT                                phosphotransferase activity.
FT                                {ECO:0000269|PubMed:15968458}.
FT   MUTAGEN     233    233       F->A: Almost complete loss of
FT                                nucleotidase and phosphotransferase
FT                                activity. {ECO:0000269|PubMed:15968458}.
FT   MUTAGEN     234    234       D->N: No effect on nucleotidase and
FT                                phosphotransferase activity.
FT                                {ECO:0000269|PubMed:15968458}.
FT   CONFLICT     95     95       R -> K (in Ref. 10; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    144    144       E -> Q (in Ref. 10; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    329    329       N -> R (in Ref. 10; AA sequence).
FT                                {ECO:0000305}.
FT   HELIX        65     78       {ECO:0000244|PDB:2VKQ}.
FT   HELIX        80     82       {ECO:0000244|PDB:2VKQ}.
FT   STRAND       83     87       {ECO:0000244|PDB:2VKQ}.
FT   TURN         90     92       {ECO:0000244|PDB:2VKQ}.
FT   STRAND       96     98       {ECO:0000244|PDB:2VKQ}.
FT   HELIX       106    111       {ECO:0000244|PDB:2VKQ}.
FT   HELIX       118    135       {ECO:0000244|PDB:2VKQ}.
FT   STRAND      138    140       {ECO:0000244|PDB:2VKQ}.
FT   HELIX       142    163       {ECO:0000244|PDB:2VKQ}.
FT   HELIX       167    169       {ECO:0000244|PDB:2VKQ}.
FT   HELIX       170    175       {ECO:0000244|PDB:2VKQ}.
FT   HELIX       185    194       {ECO:0000244|PDB:2VKQ}.
FT   STRAND      199    206       {ECO:0000244|PDB:2VKQ}.
FT   HELIX       207    216       {ECO:0000244|PDB:2VKQ}.
FT   STRAND      224    229       {ECO:0000244|PDB:2VKQ}.
FT   STRAND      231    233       {ECO:0000244|PDB:2VKQ}.
FT   STRAND      237    242       {ECO:0000244|PDB:2VKQ}.
FT   HELIX       252    258       {ECO:0000244|PDB:2VKQ}.
FT   HELIX       260    264       {ECO:0000244|PDB:2VKQ}.
FT   TURN        265    268       {ECO:0000244|PDB:2VKQ}.
FT   STRAND      271    279       {ECO:0000244|PDB:2VKQ}.
FT   HELIX       280    283       {ECO:0000244|PDB:2VKQ}.
FT   TURN        284    287       {ECO:0000244|PDB:2VKQ}.
FT   STRAND      292    300       {ECO:0000244|PDB:2VKQ}.
FT   HELIX       304    312       {ECO:0000244|PDB:2VKQ}.
FT   STRAND      315    320       {ECO:0000244|PDB:2VKQ}.
FT   HELIX       326    335       {ECO:0000244|PDB:2VKQ}.
SQ   SEQUENCE   336 AA;  37948 MW;  C5D75CCF1BB61021 CRC64;
     MRAPSMDRAA VARVGAVASA SVCALVAGVV LAQYIFTLKR KTGRKTKIIE MMPEFQKSSV
     RIKNPTRVEE IICGLIKGGA AKLQIITDFD MTLSRFSYKG KRCPTCHNII DNCKLVTDEC
     RKKLLQLKEK YYAIEVDPVL TVEEKYPYMV EWYTKSHGLL VQQALPKAKL KEIVAESDVM
     LKEGYENFFD KLQQHSIPVF IFSAGIGDVL EEVIRQAGVY HPNVKVVSNF MDFDETGVLK
     GFKGELIHVF NKHDGALRNT EYFNQLKDNS NIILLGDSQG DLRMADGVAN VEHILKIGYL
     NDRVDELLEK YMDSYDIVLV QDESLEVANS ILQKIL
//
